Patents by Inventor Andrew Peter Cridland

Andrew Peter Cridland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY
    Publication number: 20240016941
    Abstract: The invention provides a combinations and pharmaceutical compositions comprising (i) a compound which is an indane according to Formula (I) or a pharmaceutically acceptable salt thereof; and (ii) one or more CFTR modulator; wherein R1, R2, R3, R4, n, Lk, (A), G and m are as defined herein. Also provided are therapeutic uses of such combinations and compositions in the treatment of conditions such as cystic fibrosis.
    Type: Application
    Filed: March 23, 2021
    Publication date: January 18, 2024
    Applicant: Antabio SAS
    Inventors: Martin Everett, Simon Leiris, David Thomas Davies, Nicolas Sprynski, Lilha Beyria, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, Richard Leonard Elliott, David Edward Clark
  • ENZYME INHIBITORS
    Publication number: 20220298141
    Abstract: The present invention provides compounds of formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, B, and, n, are as defined herein.
    Type: Application
    Filed: August 21, 2019
    Publication date: September 22, 2022
    Inventors: Rebecca Louise DAVIE, Hannah Joy EDWARDS, David Michael EVANS, Simon Teanby HODGSON, Andrew Peter CRIDLAND, Emanuela GANCIA, Erica Lee GOLDSMITH, Paul Stuart HINCHLIFFE, Karamjit Singh JANDU, Alun John SMITH
  • ENZYME INHIBITORS
    Publication number: 20220298138
    Abstract: The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, Y, n, R1, R2A, R2B, R3 and *1 are as defined herein.
    Type: Application
    Filed: August 21, 2019
    Publication date: September 22, 2022
    Inventors: Rebecca Louise DAVIE, Hannah Joy EDWARDS, David Michael EVANS, Simon Teanby HODGSON, Sally Louise MARSH, Alessandro MAZZACANI, David Philip ROOKER, Michael John STOCKS, Andrew Peter CRIDLAND, Emanuela GANCIA, Julie Nicole HAMBLIN, Paul Stuart HINCHLIFFE, Stefano LEVANTO, Terence Aaron PANCHAL, Iain Robert MILLER
  • INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION
    Publication number: 20220112169
    Abstract: The invention relates to a compound which is an indane according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, L, n and p are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics.
    Type: Application
    Filed: July 25, 2019
    Publication date: April 14, 2022
    Applicant: Antabio SAS
    Inventors: Simon Leiris, David Thomas Davies, Martin Everett, Nicolas Sprynski, Lilha Beyria, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, Richard Leonard Elliott, David Edward Clark
  • INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION
    Publication number: 20210347748
    Abstract: The invention relates to a compound which is an indane according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, n and p are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics.
    Type: Application
    Filed: July 25, 2019
    Publication date: November 11, 2021
    Applicant: Antabio SAS
    Inventors: Simon Leiris, David Thomas Davies, Martin Everett, Nicolas Sprynski, Lilha Beyria, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, Richard Leonard Elliott, David Edward Clark
  • Chemical compounds as antibiotics
    Patent number: 11000511
    Abstract: The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p, q, L, X and m are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics. The compounds can also be used in vitro, for example in cleaning compositions.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: May 11, 2021
    Assignee: Antabio SAS
    Inventors: Simon Leiris, David Thomas Davies, Martin Everett, Nicolas Sprynski, Jonathan Mark Sutton, Michael Steven Bodnarchuk, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, David Edward Clark, Richard Leonard Elliott, Lilha Beyria
  • CHEMICAL COMPOUNDS AS ANTIBIOTICS
    Publication number: 20200155509
    Abstract: The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p, q, L, X and m are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics. The compounds can also be used in vitro, for example in cleaning compositions.
    Type: Application
    Filed: March 21, 2018
    Publication date: May 21, 2020
    Applicant: Antabio SAS
    Inventors: Simon LEIRIS, David Thomas DAVIES, Martin EVERETT, Nicolas SPRYNSKI, Jonathan Mark SUTTON, Michael Steven BODNARCHUK, Thomas David PALLIN, Andrew Peter CRIDLAND, Toby Jonathan BLENCH, David Edward CLARK, Richard Leonard ELLIOTT, Lilha BEYRIA
  • Derivatives of [1, 2, 4] triazolo [4, 3-a] pyridine as P38—MAP kinase inhibitors
    Patent number: 9573949
    Abstract: Mitogen activated protein kinase (MAPK) inhibitors disclosed herein are useful for the treatment of diseases of the respiratory tract, such as chronic eosinophilic pneumonia, asthma, COPD, adult respiratory distress syndrome (ARDS), exacerbation of airways hyper-reactivity consequent to other drug therapy, and airways disease that is associated with pulmonary hypertension.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: February 21, 2017
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Andrew Peter Cridland, Christopher Hurley
  • Kinase inhibitors
    Patent number: 9527846
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: December 27, 2016
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Monique Bodil Van Niel, Nicholas Charles Ray, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani, Andrew Peter Cridland, Christopher Hurley
  • Kinase inhibitors
    Patent number: 9440974
    Abstract: Compounds of formula (I) described herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: September 13, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Lilian Alcaraz, Christopher Hurley, Andrew Peter Cridland, Andrew Stephen Robert Jennings
  • KINASE INHIBITORS
    Publication number: 20160229852
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Application
    Filed: April 18, 2016
    Publication date: August 11, 2016
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Monique Bodil VAN NIEL, Nicholas Charles RAY, Lilian ALCARAZ, Terry Aaron PANCHAL, Andrew Stephen Robert JENNINGS, Elisabetta ARMANI, Andrew Peter CRIDLAND, Christopher HURLEY
  • DERIVATIVES OF [1, 2, 4] TRIAZOLO [4, 3 - A] PYRIDINE AS P38 - MAP KINASE INHIBITORS
    Publication number: 20160108040
    Abstract: This invention relates to compounds selected in the group consisting of compounds of formula (Ia) to (Id) and compositions, that are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Application
    Filed: June 6, 2013
    Publication date: April 21, 2016
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Lilian ALCARAZ, Terry Aaron PANCHAL, Andrew Stephen, Robert JENNINGS, Andrew Peter CRIDLAND, Christopher HURLEY
  • Kinase inhibitors
    Patent number: 9315503
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: April 19, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Monique Bodil Van Niel, Nicholas Charles Ray, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani, Andrew Peter Cridland, Christopher Hurley
  • KINASE INHIBITORS
    Publication number: 20160016953
    Abstract: Compounds of formula (I) described herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract
    Type: Application
    Filed: September 29, 2015
    Publication date: January 21, 2016
    Applicant: CHIESI FARMACEUTICI S.p.A
    Inventors: Lilian ALCARAZ, Christopher HURLEY, Andrew Peter CRIDLAND, Andrew Stephen Robert JENNINGS
  • KINASE INHIBITORS
    Publication number: 20150344475
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Application
    Filed: August 6, 2015
    Publication date: December 3, 2015
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Monique Bodil VAN NIEL, Nicholas Charles Ray, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani, Andrew Peter Cridland, Christopher Hurley
  • Kinase inhibitors
    Patent number: 9181242
    Abstract: This invention relates to compounds and compositions that are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: November 10, 2015
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Lilian Alcaraz, Christopher Hurley, Andrew Peter Cridland, Andrew Stephen Robert Jennings
  • Kinase inhibitors
    Patent number: 9145413
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: September 29, 2015
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Monique Bodil Van Niel, Nicholas Charles Ray, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani, Andrew Peter Cridland, Christopher Hurley
  • Kinase inhibitors
    Patent number: 9139584
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: September 22, 2015
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Monique Bodil Van Niel, Nicholas Charles Ray, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani, Andrew Peter Cridland, Christopher Hurley
  • Kinase inhibitors
    Patent number: 9029373
    Abstract: Compounds of formula (I): wherein R2, W, A, Y, and R1 are as defined in the specification, and pharmaceutically acceptable salts thereof, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: May 12, 2015
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Monique Bodil Van Niel, Nicholas Charles Ray, Andrew Peter Cridland, Christopher Hurley, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani
  • KINASE INHIBITORS
    Publication number: 20150080375
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Application
    Filed: October 14, 2014
    Publication date: March 19, 2015
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Monique Bodil Van Niel, Nicholas Charles Ray, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani, Andrew Peter Cridland, Christopher Hurley